Pharma Business - October 3, 2024
AstraZeneca’s Calquence granted Priority Review in the US
AstraZeneca’s supplemental New Drug Application (sNDA) for Calquence has been accepted and granted Priority Review in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL).
Pharma Business - October 2, 2024
AstraZeneca’s Enhertu granted Priority Review in the US
AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting based on the positive results from the DESTINY-Breast06 Phase III trial which compared Enhertu to chemotherapy.
Financing - October 2, 2024
Spago Nanomedical enters a new phase
The Board of Directors of Spago Nanomedical has decided that the company's resources will be focused on the development of Tumorad with the company's primary priority being the execution of the ongoing clinical study Tumorad-01 with the candidate drug 177Lu-SN201.
Financing - October 2, 2024
Senzime carries out a directed share issue of SEK 86 million
The board of directors of Senzime has resolved on a directed share issue of a maximum of 13 873 000 shares at the subscription price of SEK 6.20 per share.
Financing - October 2, 2024
Sanofi invests in Vicore
Vicore Pharma Holding has announced an investment from Sanofi in Vicore through a commitment to subscribe for shares in the ongoing rights issue corresponding to a total of approximately USD 10 million.
Clinical Trials Medtech - October 1, 2024
Elekta presents promising initial results from the UNITED trial
Jay Detsky, radiation oncologist at Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada, has presented initial cancer control outcomes from the UNITED trial (Unity-Based MR-Linac Guided Adaptive Radiotherapy for High Grade Glioma).
